Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Myeloproliferative Disorders × Rivaroxaban × 90 days × Clear all

Sponsor

Conditions

Venous Thromboembolism 2 Pulmonary Embolism 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma 1 Leukemia 1 Hematologic Neoplasms 1 Embolism 1

Interventions

fludarabine 8 Specimen Handling 8 Biopsy 8 venetoclax 6 Azacitidine 6 Whole-Body Irradiation 5 Busulfan 5 ruxolitinib 4 decitabine and cedazuridine drug combination 4 Cyclophosphamide 4 fludarabine phosphate 3 Tacrolimus 3 Mycophenolic Acid 3 Injections 3 Cytarabine 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 nilotinib 2 asciminib 2 Therapeutics 2 Stem Cell Transplantation 2 Peripheral Blood Stem Cell Transplantation 2 Melphalan 2 Liposomes 2 Granulocyte Colony-Stimulating Factor 2 Decitabine 2 Daunorubicin 2 Cyclosporins 2 CPX-351 2 Blood Specimen Collection 2 ponatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡